Measuring cancer markers in fluid around the lungs in non-small cell lung cancer
Measures PD-L1, ALK and EGFR in lung fluid of adults with non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study.
Key facts
- Where
- Næstved, DenmarkSee the site
Where in Denmark
- Næstved Sygehus, department of pulmonary medicineNæstved, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Naestved Hospital
- Trial code
- NCT04806412
- Record updated
- 24 June 2026
- Original description
Oncological treatment of patients with disseminated non-small cell lung cancer (NSCLC) is depending on the status of programmed death-ligand 1 (PD-L1), anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), so called oncodrivers. These can be measured in pleural fluid, but the prevalence is uncertain. In a prospective study, the research team aim to measure PD-L1, ALK and EGFR in patients with pleural fluid cytology positive for NSCLC to report the prevalence. Also, the study will investigate if the chance of obtaining oncodriver status is depending on the volume analysed and how the lack of oncodrivers influence the following work-up.Read full original descriptionShow less
The Prevalence of Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study.
Oncological treatment of patients with disseminated non-small cell lung cancer (NSCLC) is depending on the status of programmed death-ligand 1 (PD-L1), anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), so called oncodrivers. These can be measured in pleural fluid, but the prevalence is uncertain. In a prospective study, the research team aim to measure PD-L1, ALK and EGFR in patients with pleural fluid cytology positive for NSCLC to report the prevalence. Also, the study will investigate if the chance of obtaining oncodriver status is depending on the volume analysed and how the lack of oncodrivers influence the following work-up.
Inclusion: Age ≥ 18 years; Pleural effusion known or suspected of association with NSCLC (pleural fluid cytology positive for cells from NSCLC); Patients must be able to give informed consent.
Exclusion: Full oncodriver status measured in any pleural fluid in current work-up; Inability to understand written or spoken Danish.